Lupin Bioresearch Centre completes USFDA inspection with no observations

Global pharma major Lupin Limited (Lupin) announced that the United States Food and Drug Administration (U.S. FDA) has completed an inspection of its Bioresearch Centre in Pune, India. Lupin Bioresearch Centre conducts BA/BE, PK/PD, In-vitro BE and biosimilar studies. The inspection closed without any observation.

"We are pleased to announce that the Lupin Bioresearch Centre has successfully undergone its seventh consecutive onsite inspection, reaffirming our commitment to patient safety and our superior quality and compliance standards," said Nilesh Gupta, Managing Director, Lupin.

Alembic announces Successful completion of USFDA inspection at Derma facility at Karakhadi

Alembic Pharmaceuticals Limited has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Derma Facility located at Karakhadi without any observations. The inspection was conducted from 6th March, 2023 to 10th March, 2023.